Cell and Gene Commercialization

  1. Driving Gene Therapy Beyond Rare Disease Will Define The Next Era Of CGT 6/2/2026

    Gene therapy’s next test is not proving it works, but proving it can scale.

  2. Cell And Gene Therapies – U.S. Payer Trends 5/20/2026

    Gain insights from U.S. payer interviews covering coverage processes, evidence requirements, and engagement strategies to accelerate market access from late-stage development through commercialization.

  3. Price Matters - Why Dash Believes In Transparency 5/15/2026

    Opaque pricing slows decisions and erodes trust. Transparency clarifies cost drivers, improves budgeting, enables confident sourcing, and strengthens long-term R&D partnerships.

  4. Can A Biotech Create A CDMO Market? 5/11/2026

    Can a biotech create a CDMO market? GeoVax, an infectious disease/oncology biotech, may have just done so. David Dodd, CEO, believes we should all concentrate more on whether the outsourcing model can align with evolving technology platforms. Both sponsors and CDMOs may need to change things up.

  5. Cell And Gene Therapies: The Emerging Reality For Scalable Market Readiness 5/8/2026

    Mainstream biopharma’s commercialization playbook isn’t working for cell and gene therapies. Orgs that invest in scalable platforms (and more) will see better success.

  6. 9 Logistics And Distribution Recommendations For CGTs 5/6/2026

    Cell and gene therapy commercialization requires tailored logistics strategies. Explore nine recommendations covering site readiness, reimbursement gaps, packaging, testing, and coordination.

  7. Materials Matter: Reframing Raw Material Strategy In Cell And Gene Therapy Development 5/1/2026

    Scaling iPSC-based therapies from lab to CGMP manufacturing demands tightly controlled cryopreservation, risk-based QC, and strategic automation to preserve cell viability, consistency, and regulatory readiness.

  8. Regeneron Advances In Vivo Gene Therapy For Hearing Loss 5/1/2026

    Regeneron’s Otarmeni marks a major CGT milestone, showing that in vivo gene therapy can restore hearing in OTOF-related deafness while expanding the field’s clinical and delivery possibilities.

  9. Cell And Gene Therapy CDMOs: On The Path To $75 Billion in Services? 4/30/2026

    Cell and gene therapy (CGT) developers – and thus their service providers – have had their share of ups and downs. But what do the promise and uneven realities of these therapies add up to in the development and manufacturing outsourcing sector? According to a Towards Healthcare report, despite the bumps in the road, in 2025 the global CGT CDMO market grew to $8.2 billion. What of future predictions? Here's a detailed analysis.

  10. How AI Could Clear Logistics Roadblocks Limiting Patient Access To CGT 4/23/2026

    Patient access often gets mischaracterized solely as a cost and pricing issue. A discussion among industry leaders reaches a deeper, more complex conclusion.